Treatment Market is experiencing significant growth due to the increasing prevalence of iron deficiency anemia worldwide. IDA is one of the most common nutritional deficiencies, affecting a large ...

ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ...

When CSL acquired Vifor, it raised eyebrows, given initial integration hurdles and generic competition for some Vifor ...

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

CSL shares tumbled 4.95% on the day of its half-year results after revenue, net profits and dividends missed market expectations Behring and Vifor outperformed, while Seqirus underperformed due to ...

Wilsons Advisory analyst Dr Shane Storey said the result was “compositionally wild” however, with the Behring and Vifor divisions meeting guidance while the Seqirus virus arm delivered a “whopping ...

Australian biopharmaceutical company CSL said on Tuesday that falling immunisation rates in the U.S., its largest market, weighed on its vaccine sales and first-half profit growth, sending its shares ...

Revenue from CSL's flu vaccine-making business dropped sharply in the first half of the financial year amid a significant fall in immunisation rates, particularly in the US.